KIT and glioblastoma: Dasatinib inhibits multiple tyrosine kinases which are reported to be overexpressed or constitutively active in GBM such as the SRC family kinases, Kit, macrophage colony-stimulating factor receptor, PDGFR-α and–β, EphB1, EpHB2 and EphB4 [29–32].